Merck PE Ratio 2012-2026 | MRK
Current and historical p/e ratio for Merck (MRK) from 2012 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Merck PE ratio as of June 12, 2026 is 13.54.
| Merck PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-06-12 | 119.05 | 33.54 | |
| 2026-03-31 | 120.29 | $3.55 | 33.88 |
| 2025-12-31 | 104.49 | $7.28 | 14.35 |
| 2025-09-30 | 82.61 | $7.58 | 10.90 |
| 2025-06-30 | 77.15 | $6.50 | 11.87 |
| 2025-03-31 | 86.61 | $6.88 | 12.59 |
| 2024-12-31 | 95.17 | $6.74 | 14.12 |
| 2024-09-30 | 107.78 | $4.77 | 22.59 |
| 2024-06-30 | 116.72 | $5.39 | 21.65 |
| 2024-03-31 | 123.66 | $0.90 | 137.40 |
| 2023-12-31 | 101.53 | $0.14 | 725.19 |
| 2023-09-30 | 95.18 | $1.80 | 52.88 |
| 2023-06-30 | 105.96 | $1.22 | 86.86 |
| 2023-03-31 | 97.05 | $5.12 | 18.96 |
| 2022-12-31 | 100.51 | $5.71 | 17.60 |
| 2022-09-30 | 77.50 | $6.01 | 12.90 |
| 2022-06-30 | 81.39 | $6.53 | 12.46 |
| 2022-03-31 | 72.66 | $5.59 | 13.00 |
| 2021-12-31 | 67.27 | $5.14 | 13.09 |
| 2021-09-30 | 65.30 | $2.84 | 22.99 |
| 2021-06-30 | 67.02 | $2.20 | 30.46 |
| 2021-03-31 | 62.85 | $2.77 | 22.69 |
| 2020-12-31 | 66.11 | $2.78 | 23.78 |
| 2020-09-30 | 66.51 | $4.52 | 14.71 |
| 2020-06-30 | 61.56 | $4.10 | 15.01 |
| 2020-03-31 | 60.76 | $3.95 | 15.38 |
| 2019-12-31 | 71.24 | $3.81 | 18.70 |
| 2019-09-30 | 65.49 | $3.58 | 18.29 |
| 2019-06-30 | 64.80 | $3.57 | 18.15 |
| 2019-03-31 | 63.85 | $3.17 | 20.14 |
| 2018-12-31 | 58.26 | $2.32 | 25.11 |
| 2018-09-30 | 53.72 | $1.25 | 42.97 |
| 2018-06-30 | 45.65 | $0.50 | 91.30 |
| 2018-03-31 | 40.65 | $0.58 | 70.09 |
| 2017-12-31 | 41.63 | $0.87 | 47.85 |
| 2017-09-30 | 46.97 | $1.05 | 44.74 |
| 2017-06-30 | 46.68 | $1.85 | 25.23 |
| 2017-03-31 | 45.94 | $1.57 | 29.26 |
| 2016-12-31 | 42.26 | $1.41 | 29.97 |
| 2016-09-30 | 44.46 | $1.96 | 22.68 |
| 2016-06-30 | 40.74 | $1.82 | 22.38 |
| 2016-03-31 | 37.11 | $1.63 | 22.77 |
| 2015-12-31 | 36.73 | $1.56 | 23.54 |
| 2015-09-30 | 34.05 | $3.72 | 9.15 |
| 2015-06-30 | 38.91 | $3.39 | 11.48 |
| 2015-03-31 | 38.99 | $3.83 | 10.18 |
| 2014-12-31 | 38.22 | $4.07 | 9.39 |
| 2014-09-30 | 39.59 | $1.83 | 21.63 |
| 2014-06-30 | 38.36 | $1.90 | 20.19 |
| 2014-03-31 | 37.36 | $1.52 | 24.58 |
| 2013-12-31 | 32.68 | $1.47 | 22.23 |
| 2013-09-30 | 30.81 | $1.50 | 20.54 |
| 2013-06-30 | 29.79 | $1.68 | 17.73 |
| 2013-03-31 | 28.09 | $1.96 | 14.33 |
| 2012-12-31 | 25.77 | $2.00 | 12.88 |
| 2012-09-30 | 28.12 | $2.18 | 12.90 |
| 2012-06-30 | 25.78 | $2.17 | 11.88 |
| 2012-03-31 | 23.46 | $2.24 | 10.47 |
| 2011-12-31 | 22.78 | $2.02 | 11.28 |
| 2011-09-30 | 19.52 | $1.38 | 14.15 |
| 2011-06-30 | 20.82 | $0.94 | 22.15 |
| 2011-03-31 | 19.26 | $0.53 | 36.35 |
| 2010-12-31 | 20.79 | $0.28 | 74.25 |
| 2010-09-30 | 21.01 | $3.07 | 6.84 |
| 2010-06-30 | 19.75 | $4.57 | 4.32 |
| 2010-03-31 | 20.86 | $5.07 | 4.12 |
| 2009-12-31 | 20.20 | $5.65 | 3.58 |
| 2009-09-30 | 17.31 | $3.80 | 4.56 |
| 2009-06-30 | 15.12 | $2.70 | 5.60 |
| 2009-03-31 | 14.26 | $2.78 | 5.13 |
| 2008-12-31 | 15.94 | $3.63 | 4.39 |
| 2008-09-30 | 16.32 | $2.09 | 7.81 |
| 2008-06-30 | 19.27 | $2.28 | 8.45 |
| 2008-03-31 | 19.21 | $2.23 | 8.62 |
| 2007-12-31 | 29.17 | $1.49 | 19.57 |
| 2007-09-30 | 25.77 | $2.47 | 10.43 |
| 2007-06-30 | 24.64 | $2.20 | 11.20 |
| 2007-03-31 | 21.70 | $2.12 | 10.23 |
| 2006-12-31 | 21.23 | $2.03 | 10.46 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $299.893B | $65.011B |
| Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |